Analysis of LPL gene expression in patients with chronic lymphocytic leukemia [Текст] / N. Bilous [та ін.] // Экспериментальная онкология. - 2019. - Т. 41, № 1. - С. 39-45. - Bibliogr. at the end of the art. MeSH-головна: ЛЕЙКОЗ ЛИМФОЦИТАРНЫЙ ХРОНИЧЕСКИЙ B-КЛЕТОЧНЫЙ -- LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL (диагностика, патофизиология, этиология) ПРОГНОЗ -- PROGNOSIS ПРОТИВООПУХОЛЕВОЙ КОМБИНИРОВАННОЙ ХИМИОТЕРАПИИ ПРОТОКОЛЫ -- ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS (фармакология) ИММУНОТЕРАПИЯ -- IMMUNOTHERAPY (использование, методы, тенденции) НОВООБРАЗОВАНИЙ МАРКЕРЫ БИОЛОГИЧЕСКИЕ -- TUMOR MARKERS, BIOLOGICAL (анализ) СТАТИСТИЧЕСКАЯ ОБРАБОТКА ДАННЫХ -- DATA INTERPRETATION, STATISTICAL Кл.слова (ненормовані): Мутационный статус IGHV-генов Анотація: The IGHV mutational status is one of the most important markers for chronic lymphocytic leukemia (CLL) prognostication. Lipoprotein lipase (LPL) gene expression was found to correlate with IGHV status and was suggested as its surrogate marker. Recent data reported that LPL expression might be influenced by pivotal signalling pathways in CLL. This study aimed to assess LPL gene expression in relation to key immunogenetic and molecular markers of CLL, including IGHV mutational status, B-cell receptor (BCR) stereotypy, TP53, NOTCH1, and SF3B1 gene mutations. Materials and Methods: Expression of LPL mRNA was measured in peripheral blood mononuclear cells of 73 CLL patients by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR). IGHV, NOTCH1, TP53, and SF3B1 gene mutation analysis was performed by PCR amplification and direct sequencing. Results: 44 of 73 (60%) CLL cases were categorized as LPL-positive based on the cut-off value established by ROC (receiver operating characteristic) curve analysis. LPL expression was significantly associated with IGHV mutation status (r = 0.684; p < 0.0001) and tended to correlate with presence of NOTCH1 gene mutations (p = 0.113). BCR stereotyped cases showed higher LPL expression values in comparison to unstereotyped cases in the LPL-positive group of patients (p = 0.041). LPL expression was associated with a shorter overall survival in the entire СLL group (median 107 vs 143, p = 0.048) as well as in Binet A patients, albeit with borderline significance (median 139 vs not reached, p = 0.086). Conclusion: LPL expression was found to be closely correlated with IGHV gene mutational status and overall survival, proving LPL as prognostic marker in CLL. Our results also indicate a possible relationship between aberrant expression of LPL and BCR- and NOTCH1-dependent signalling pathways Дод.точки доступу: Bilous, N. Abramenko, I. Chumak, A. Dyagil, I. Martina, Z. Вільних прим. немає